{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:01:18Z","timestamp":1793466078380,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.gim.2025.101590","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:16:57Z","timestamp":1758701817000},"page":"101590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Infantile-onset Pompe disease entering adulthood: Insights from 2 decades of enzyme replacement therapy experience"],"prefix":"10.1016","volume":"27","author":[{"given":"Neha","family":"Regmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kenney-Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Stafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Malinzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail A.","family":"Spiridigliozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Boggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip Brian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Case","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8251-909X","authenticated-orcid":false,"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gim.2025.101590_bib1","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II, acid \u03b1-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"issue":"5","key":"10.1016\/j.gim.2025.101590_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.gim.2025.101590_bib3","first-page":"45","article-title":"Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease","volume":"23","author":"Pena","year":"2015","journal-title":"JIMD Rep"},{"issue":"3","key":"10.1016\/j.gim.2025.101590_bib4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol Clin"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.gim.2025.101590_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"8","key":"10.1016\/j.gim.2025.101590_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.gim.2025.101590_bib9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2025.101590_bib10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2025.101590_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2025.101590_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"issue":"16","key":"10.1016\/j.gim.2025.101590_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy\u2013treated CRIM-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.gim.2025.101590_bib14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.gim.2025.101590_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.gim.2025.101590_bib16","article-title":"Characterization of immune response in cross-reactive immunological material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"13","key":"10.1016\/j.gim.2025.101590_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108119","article-title":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"141","author":"Kenney-Jung","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2025.101590_bib21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jimd.12736","article-title":"Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning","volume":"47","author":"van Den Dorpel","year":"2024","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)--A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"1","key":"10.1016\/j.gim.2025.101590_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101590_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jpeds.2006.12.052","article-title":"Six-minute walk test in children and adolescents","volume":"150","author":"Geiger","year":"2007","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.gim.2025.101590_bib25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1590\/S1413-35552012005000122","article-title":"Reference equations for the six-minute walk distance based on a Brazilian multicenter study","volume":"17","author":"Britto","year":"2013","journal-title":"Braz J Phys Ther"},{"issue":"3","key":"10.1016\/j.gim.2025.101590_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1469-8749.1989.tb04003.x","article-title":"The gross motor function measure: a means to evaluate the effects of physical therapy","volume":"31","author":"Russell","year":"1989","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"10.1016\/j.gim.2025.101590_bib28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.23340","article-title":"New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy","volume":"45","author":"Angelini","year":"2012","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10545-011-9388-3","article-title":"The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients","volume":"35","author":"van Capelle","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2025.101590_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2021.10.002","article-title":"Physical therapy assessment and whole-body magnetic resonance imaging findings in children with glycogen storage disease type IIIa: a clinical study and review of the literature","volume":"134","author":"Paschall","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.gim.2025.101590_bib31","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.apmr.2004.11.049","article-title":"Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients","volume":"86","author":"Crary","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"issue":"6","key":"10.1016\/j.gim.2025.101590_bib32","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1212\/WNL.0000000000009979","article-title":"Novel approaches to quantify CNS involvement in children with Pompe disease","volume":"95","author":"Korlimarla","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal Biochem"},{"key":"10.1016\/j.gim.2025.101590_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1196\/annals.1340.028","article-title":"White matter and behavioral neurology","volume":"1064","author":"Filley","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101590_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.gim.2025.101590_bib37","article-title":"Optimizing clinical outcomes: the journey of twins with CRIM-negative infantile-onset Pompe disease on high-dose enzyme replacement therapy and immunomodulation","volume":"41","author":"Fares","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.gim.2025.101590_bib38","article-title":"Avalglucosidase alfa in infantile-onset Pompe disease: a snapshot of real-world experience in Italy","volume":"40","author":"Fiumara","year":"2024","journal-title":"Mol Genet Metab Rep"},{"issue":"5","key":"10.1016\/j.gim.2025.101590_bib39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.gim.0000217786.79173.a8","article-title":"Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease","volume":"8","author":"Cook","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2025.101590_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","article-title":"Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase","volume":"269","author":"van Capelle","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.gim.2025.101590_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.gim.0000195896.04069.5f","article-title":"Electrocardiographic response to enzyme replacement therapy for Pompe disease","volume":"8","author":"Ansong","year":"2006","journal-title":"Genet Med"},{"issue":"22","key":"10.1016\/j.gim.2025.101590_bib42","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/01.CIR.0000075270.13497.2B","article-title":"Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy","volume":"107","author":"Arad","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.gim.2025.101590_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ymgme.2010.07.011","article-title":"Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy","volume":"101","author":"Barker","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2025.101590_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2018.12.214","article-title":"Quantitative evaluation of white matter hyperintensities in the central nervous system in infantile Pompe disease","volume":"126","author":"Korlimarla","year":"2019","journal-title":"Mol Genet Metab"},{"issue":"0","key":"10.1016\/j.gim.2025.101590_bib46","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1540\/jsmr.54.100","article-title":"The impact of Pompe disease on smooth muscle: a review","volume":"54","author":"McCall","year":"2018","journal-title":"J Smooth Muscle Res"},{"issue":"6","key":"10.1016\/j.gim.2025.101590_bib47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3928\/01913913-20140813-01","article-title":"Ocular and histologic findings in a series of children with infantile Pompe disease treated with enzyme replacement therapy","volume":"51","author":"Prakalapakorn","year":"2014","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"5","key":"10.1016\/j.gim.2025.101590_bib48","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/nau.24950","article-title":"Prevalence of lower urinary tract symptoms in children with early-treated infantile-onset Pompe disease: a single-centre cross-sectional study","volume":"41","author":"Chen","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.gim.2025.101590_bib49","first-page":"59","article-title":"Lower urinary tract symptoms and incontinence in children with Pompe disease","volume":"28","author":"Ajay","year":"2016","journal-title":"JIMD Rep"},{"issue":"3","key":"10.1016\/j.gim.2025.101590_bib50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ppul.24621","article-title":"Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: a case series","volume":"55","author":"ElMallah","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.gim.2025.101590_bib51","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13023-021-01817-1","article-title":"Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy","volume":"16","author":"Hsueh","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.gim.2025.101590_bib52","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.gim.2025.101590_bib53","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025002370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025002370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:03:46Z","timestamp":1764302626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360025002370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1098360025002370"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101590","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infantile-onset Pompe disease entering adulthood: Insights from 2 decades of enzyme replacement therapy experience","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101590"}}